Parkman Healthcare Partners LLC
SEC Form 13F institutional filer · CIK 0001777015
13F-HR · 15 reported holdings · 2026-03-31
Reported long-US-equity value
$0.32B
Top-10 concentration
88.4%
Parkman Healthcare Partners LLC — $321M AUM allocation strategy
Parkman Healthcare Partners LLC files SEC Form 13F and reports $321M of long US equity value across 15 reported holdings for 2026-03-31.
Its largest sector bet is Health Care 100.0%.
The top 10 holdings account for 88% of reported value — a conviction-weighted book concentrated in its best ideas. The sector and industry splits below are of the same reported value. Track quarter-over-quarter adds, trims, new positions and exits below — sourced from SEC 13F filings, public domain.
Parkman Healthcare Partners LLC — latest SEC 13F insights
Reported long-US-equity value (13F AUM)
$321M
total across 15 reported holdings · 2026-03-31 · excludes shorts, cash, non-US
Top-10 concentration
88% of value
higher = narrower conviction; lower = spread / hedging
Biggest adds (shares)
+$ZBH +119K sh · +$10.8M+$DXCM +102K sh · +$4.33M+$IQV +51.5K sh · +$6.84M
Biggest trims (shares)
−$CVS −62.9K sh · −$7.91M−$BSX −51.8K sh · −$19.6M−$COO −35.5K sh · −$3.85M
Exited to nil (held last quarter, gone now)
$MTD ($15.3M last qtr)$A ($13.6M last qtr)$DHR ($13.5M last qtr)$UNH ($10.5M last qtr)$BIIB ($6.23M last qtr)
Sector allocation (share of reported value)
- $XLVHealth Care100.0%—
each slice is a share of the reported long-US-equity value — smaller sectors and the rest of the book roll into “Other holdings”
Qtr shift = share-point change vs the prior quarter's filing — first period tracked for this filer; the column fills in with the next quarterly refresh.
Industry allocation (share of reported value)
- Health Care Equipment62.7%—
- Pharmaceuticals9.9%—
- Health Care Services8.7%—
- Life Sciences Tools & Services7.1%—
- Biotechnology5.1%—
- Health Care Distributors3.4%—
- Health Care Supplies3.1%—
the finer GICS cut of the same book — same denominator — smaller industries roll into “Other holdings”
Qtr shift = share-point change vs the prior quarter's filing — first period tracked for this filer; the column fills in with the next quarterly refresh.
Top S&P 500 holdings
10 of 10 rows · sorted by Value ↓
| Ticker | Holding | Shares | Value | Δ QoQ | Weight |
|---|---|---|---|---|---|
| $SYK | Stryker Corporation | 155K | $50.9M | +49.3K | 15.8% |
| $DXCM | DexCom Inc | 690K | $43.3M | +102K | 13.5% |
| $PODD | Insulet Corporation | 157K | $32.9M | +15.7K | 10.2% |
| $LLY | Eli Lilly and Company | 34.6K | $31.8M | — | 9.9% |
| $BSX | Boston Scientific Corporation | 449K | $28.2M | -51.8K | 8.8% |
| $CVS | CVS Health Corporation | 387K | $27.8M | -62.9K | 8.7% |
| $ZBH | Zimmer Biomet Holdings Inc | 270K | $24.4M | +119K | 7.6% |
| $ABBV | AbbVie Inc | 75K | $16.3M | — | 5.1% |
| $IQV | IQVIA Holdings Inc | 86.7K | $14.8M | +51.5K | 4.6% |
| $EW | Edwards Lifesciences Corporation | 167K | $13.4M | +16.2K | 4.2% |
…and 5 more holdings in the full 13F filing (top positions only shown).
SEC Form 13F data sets · public domain · 45-day filing lag · >$100M AUM managers · as reported
← All 13F filers·← QuantOrb.pro
How to read Δ QoQ — the five insight categories, and the caveats
The categories. Analysts, quants and retail traders look past total portfolio value to isolate actionable signals. Five categories matter.
Conviction & concentration shifts
New positions vs complete exits — a brand-new stock signals high conviction; a full liquidation suggests a broken thesis or tax-loss harvesting. Aggressive sizing — look at share count, not dollars: a 20% share increase during a drawdown is strong dip-buying. Concentration — a narrowing top-5/10 means conviction; spreading capital across more names means hedging.
Sector & macro allocation rotations
Aggregating Δ QoQ moves across sectors shows where smart money is leaning in or sneaking out — rotating out of growth into defensives or energy, for example. The fund's total long equity exposure quarter-over-quarter is a proxy for overall institutional risk appetite.
Crowding & smart-money consensus
When several managers initiate or expand the same stock in the same quarter, that is institutional consensus. Contrarian reads: top pickers buying hard into a beaten-down name the market is selling.
Derivative & option overlays
Reported call/put changes indicate whether managers are adding downside hedges or leveraging upside exposure. Note: a long increase may be half of a market-neutral pair trade.
Who reads this
| Retail "cloners" | High-conviction ideas to replicate ~45 days after quarter-end. |
| Corporate IR | Which funds bought or dumped the stock, before the next call. |
| Quant / algo traders | Cross-sectional factor inputs: flow, momentum, ownership. |
Four caveats before you trade on it
- 45-day lag — holdings are quarter-end; positions may already be closed.
- Long-only — 13Fs miss shorts, pair trades and cash.
- No non-US / fixed income — the picture is US equities plus options.
- Corporate actions — splits and spinoffs distort raw share deltas.
Newsletter signup
Free subscription. Daily trading day morning dispatch. No spam.